Zhitong Financial APP learned that Junshi Bio (01877) rose more than 8% in the afternoon and rose 8.33% to HK $43.55 as of press time, with a turnover of HK $76.897 million.
According to the news, according to the Securities Times, the online examination and approval supervision platform for investment projects in Shanghai shows that recently, the filing of Junshi's VV116 (deuterium hydrobromide Remidvir tablets) industrialization project was approved by the management committee of Zhangjiang High-tech Park.
In addition, Junshi announced that it is proposed to issue up to 70 million A shares, and the total proceeds are expected to be adjusted from the original 3.98 billion yuan to 3.969 billion yuan, of which about 3.671 billion yuan will be used for innovative drug research and development projects. about 298 million yuan will be used for the Shanghai Junshi Biotechnology headquarters and R & D base project.